VVY
|Vivoryon Therapeutics NV
AS
EUR 1.44
+0.00|+0.14%
Current Price
EUR 1.44
Change
+EUR 0.00 (0.14%)
P/E Ratio
Dividend Yield
Market Cap
44.31M
Volume
28,440
Open
EUR 1.42
Previous Close
EUR 1.44
52-Week High
EUR 3.00
52-Week Low
EUR 1.32
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monocl...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Frank T. Weber M.D.
Employees:14
Headquarters:Halle, Germany
Website:www.vivoryon.com
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions